Alphamab's cancer cash

Alphamab Oncology to push several programs through the clinic with $100M A round

Alphamab Oncology spun out from Suzhou Alphamab Co. Ltd. and raised more than $100 million in a series A round to advance multiple cancer biologics through clinical testing.

Investors in the round, which closed on Nov. 17, include Advantech

Read the full 396 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE